Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Patients with EGFR-mutant non-small cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to de novo resistance (~30%) as well as acquired resistance. Epithelial-mesenchymal transiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yochum, Zachary A., Cades, Jessica, Wang, Hailun, Chatterjee, Suman, Simons, Brian W., O’Brien, James P., Khetarpal, Susheel K., Lemtiri-Chlieh, Ghali, Myers, Kayla V., Huang, Eric H.-B., Rudin, Charles M., Tran, Phuoc T., Burns, Timothy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358506/
https://www.ncbi.nlm.nih.gov/pubmed/30171258
http://dx.doi.org/10.1038/s41388-018-0482-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358506/
https://www.ncbi.nlm.nih.gov/pubmed/30171258
http://dx.doi.org/10.1038/s41388-018-0482-y

Ejemplares similares